BridgeMD
Intervertebral Disc Regeneration by Autologous Stem Cell Transplantation
EU CTIS ID: 2024-514475-17-00
What this study is testing
To monitor patient’s response and potential side effects of AD-MSC therapy in patients suffering from DDD compared to control group.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with lumbar back pain (max 2 levels)
- age 20 to 60 yrs,
- moderate disc degeneration (Pfirman grade 2-3)
You likely can't join if
- Patients with lumbar back pain of other apparent reason such as: severe spinal stenosis, herniated disc, spondylolisthesis grade 2 or more.
- Penicillin allergies.
- Age <20yrs, >60 yrs.
- Cognitive impairment.
- Treatment with cytostatic drugs.
- High risk of bleeding (bleeding disorder, taking anticoagulants etc.).
See the full eligibility criteria
- Patients with lumbar back pain (max 2 levels)
- age 20 to 60 yrs,
- moderate disc degeneration (Pfirman grade 2-3)
- Patients with lumbar back pain of other apparent reason such as: severe spinal stenosis, herniated disc, spondylolisthesis grade 2 or more.
- Penicillin allergies.
- Age <20yrs, >60 yrs.
- Cognitive impairment.
- Treatment with cytostatic drugs.
- High risk of bleeding (bleeding disorder, taking anticoagulants etc.).
- Previous injections in disc.
- Pregnancy or breastfeeding.
- Conditions not compatible with MRI (non-compatible implants, claustrophobia, severe obesity).
- Tumors, infection or fracture in spine.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.